This is such a waste of life even responding to this non sense. Neither will close the doors. Natera just filed for an IPO and have a future in oncology. Roche is a large enough company to sustain anything. The fact that both tests are the only two on the market that actually add value to a clinic should tell you that both will be around. Sequenom sucks and fluffs all their data, and every other company just repackages illumina's crappy test and gives it a different name. The 16 other companies that do that (Quest, labcorp, progenity, good start etc.) are the joke of the industry.
